Your browser is no longer supported. Please, upgrade your browser.
Corbus Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own0.42% Shs Outstand125.03M Perf Week-6.75%
Market Cap119.08M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float123.96M Perf Month-13.54%
Income-76.70M PEG- EPS next Q-0.12 Inst Own43.60% Short Float5.32% Perf Quarter-31.58%
Sales2.70M P/S44.10 EPS this Y-27.40% Inst Trans-0.05% Short Ratio6.98 Perf Half Y-48.87%
Book/sh0.66 P/B1.44 EPS next Y8.00% ROA-66.90% Target Price- Perf Year-8.55%
Cash/sh0.85 P/C1.12 EPS next 5Y- ROE-126.30% 52W Range0.91 - 4.00 Perf YTD-23.91%
Dividend- P/FCF- EPS past 5Y-38.20% ROI-191.90% 52W High-76.22% Beta1.90
Dividend %- Quick Ratio6.00 Sales past 5Y43.40% Gross Margin- 52W Low4.52% ATR0.05
Employees76 Current Ratio6.00 Sales Q/Q-66.70% Oper. Margin- RSI (14)37.14 Volatility5.25% 4.61%
OptionableYes Debt/Eq0.24 EPS Q/Q71.40% Profit Margin- Rel Volume2.07 Prev Close1.03
ShortableYes LT Debt/Eq0.24 Earnings- Payout- Avg Volume944.86K Price0.95
Recom2.80 SMA20-8.13% SMA50-15.34% SMA200-44.98% Volume1,957,377 Change-7.66%
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Sep-08-20Downgrade BTIG Research Buy → Neutral
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Jan-11-19Reiterated Cantor Fitzgerald Overweight $36 → $38
Dec-26-18Initiated H.C. Wainwright Buy $24
Dec-07-18Initiated RBC Capital Mkts Outperform $23
Oct-24-18Initiated B. Riley FBR Buy $22
Jan-19-18Initiated Raymond James Outperform $24
Dec-14-17Reiterated Cantor Fitzgerald Overweight $24 → $28
Nov-08-17Reiterated Noble Financial Buy $16 → $20
Sep-29-17Resumed Noble Financial Buy $16
Mar-30-17Reiterated Cantor Fitzgerald Overweight $17 → $24
Nov-15-16Reiterated JMP Securities Mkt Outperform $9 → $20
Nov-11-16Reiterated Noble Financial Buy $19
Oct-21-21 09:30AM  
Sep-10-21 06:45AM  
Aug-12-21 09:45AM  
Jul-29-21 03:04PM  
Jun-24-21 08:05AM  
Jun-21-21 05:48PM  
Jun-18-21 08:38AM  
Jun-12-21 04:19AM  
Jun-03-21 02:42AM  
Jun-02-21 06:19AM  
Jun-01-21 12:26PM  
May-25-21 08:05AM  
May-19-21 09:20AM  
May-17-21 08:34AM  
May-11-21 08:05AM  
May-03-21 03:01PM  
Apr-20-21 08:05AM  
Mar-30-21 08:05AM  
Mar-18-21 12:00PM  
Mar-15-21 02:30PM  
Mar-10-21 12:59AM  
Mar-09-21 08:05AM  
Mar-08-21 08:05AM  
Mar-04-21 12:30PM  
Feb-11-21 11:29AM  
Feb-02-21 10:44AM  
Jan-20-21 08:05AM  
Jan-14-21 08:30AM  
Jan-12-21 08:49AM  
Jan-09-21 02:16AM  
Dec-07-20 10:43PM  
Dec-04-20 08:44AM  
Dec-01-20 10:28AM  
Nov-16-20 09:54AM  
Nov-12-20 08:05AM  
Nov-11-20 10:00AM  
Nov-10-20 03:31PM  
Nov-09-20 10:27AM  
Nov-03-20 08:05AM  
Oct-29-20 12:35PM  
Oct-23-20 08:05AM  
Oct-21-20 08:05AM  
Oct-08-20 08:05AM  
Oct-07-20 10:46AM  
Oct-06-20 07:05AM  
Oct-04-20 09:46AM  
Sep-25-20 08:53AM  
Sep-24-20 09:54AM  
Sep-10-20 10:01AM  
Sep-08-20 10:00AM  
Sep-04-20 09:40AM  
Aug-25-20 09:19AM  
Aug-24-20 06:30AM  
Aug-20-20 10:17AM  
Aug-16-20 08:15AM  
Aug-14-20 10:31AM  
Aug-06-20 07:05AM  
Aug-05-20 09:25AM  
Aug-03-20 08:05AM  
Jul-30-20 08:05AM  
Jul-29-20 08:05AM  
Jul-21-20 10:02AM  
Jul-17-20 04:21PM  
Jul-15-20 02:38PM  
Jul-08-20 08:05AM  
Jul-05-20 09:58PM  
Jun-29-20 08:05AM  
Jun-22-20 08:05AM  
Jun-18-20 10:56AM  
Jun-01-20 09:00AM  
May-28-20 06:53AM  
May-27-20 08:05AM  
May-22-20 08:05AM  
May-18-20 03:09AM  
May-15-20 12:00PM  
May-14-20 09:30AM  
May-11-20 09:55AM  
May-04-20 08:05AM  
Apr-30-20 04:15PM  
Apr-29-20 08:05AM  
Apr-28-20 07:05AM  
Apr-02-20 08:58AM  
Mar-14-20 08:52AM  
Mar-12-20 08:55AM  
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran Sean F.Chief Financial OfficerDec 21Option Exercise1.4087,500122,500437,110Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 21Sale1.7587,500153,125349,610Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 18Option Exercise1.0053,61053,610403,220Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 18Sale1.4053,61075,054349,610Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 16Option Exercise0.1736,9236,118386,533Dec 18 04:44 PM
Moran Sean F.Chief Financial OfficerDec 16Sale1.3236,92348,628349,610Dec 18 04:44 PM
Cohen YuvalChief Executive OfficerNov 11Buy1.214,2405,12675,330Nov 12 10:28 AM